Compare Global X Copper Miners ETF (COPX) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Copper Miners ETF vs Merck & Co., Inc. — how do they compare? Global X Copper Miners ETF trades at $84.96 (market cap $7.10B), while Merck & Co., Inc. trades at $144.98 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 49.5× Global X Copper Miners ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Global X Copper Miners ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global X Copper Miners ETF for 50 Days and Merck & Co., Inc. for 98 Days on average.
| COPX | MRK | |
|---|---|---|
Market Cap | $7.10B | $351.28B |
Volume | 2,871,128 | 7,969,665 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $96.45 | $156.43 |
52-Week Low | $57.43 | $82.49 |
Typical Hold Time | 50 Days | 98 Days |
Enterprise Value | — | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COPX trades at $84.83, up 1.5% today, but technical indicators show a bearish trend with 17 sell signals versus 2 buy signals. The ETF faces resistance at $85 with support at $79. Recent news highlights copper's strategic importance for AI infrastructure and electrification, though analysts express caution about near-term global surplus projections despite strong copper price fundamentals.
The copper miner ETF offers exposure to the AI-driven copper demand story but faces headwinds from Federal Reserve policy uncertainty and potential global supply surpluses. While long-term electrification trends support the investment thesis, near-term volatility and miner underperformance relative to copper prices present both opportunity and risk for investors.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Copper Miners ETF
COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.
Read more on COPX →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
